Shares of Catalent (CTLT) lost 0.9% on Oct. 23 with the rise in uncertainty related to its acquisition by Novo Holding following a report from Reuters on opposition from several large pharma companies as well as an alliance of U.S. consumer, patient and workers advocacy groups.CTLT and Novo Holdings, the parent company of Novo Nordisk (NVO) , entered into a merger agreement in February. Per the agreement, NVO’s parent company will acquire all outstanding shares of Catalent for $63.50 per share in cash. The ...